How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

59,638 results for

HIV Test

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

55601. Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

Status : Withdrawn First Posted : October 31, 2008 Last Update Posted : January 19, 2012 Sponsor: ViiV Healthcare Collaborator: Pfizer Information provided by (Responsible Party): ViiV Healthcare Study Details Study Description Go to Brief Summary: Confirm the safety of maraviroc when used as a component of combination antiretroviral therapy in HIV and Hepatitis co-infected patients. Condition or disease Intervention/treatment Phase Hepatitis B Human Immunodeficiency Virus Hepatitis C, Chronic Drug (...) Hepatitis Hepatitis A Hepatitis C Hepatitis B Immunologic Deficiency Syndromes Acquired Immunodeficiency Syndrome HIV Infections Hepatitis C, Chronic Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections Flaviviridae Infections Hepadnaviridae Infections DNA Virus Infections Immune System Diseases Lentivirus Infections Retroviridae Infections Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases

2008 Clinical Trials

55602. Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected Adults

. Analysis of D-dimer concentration is employed in the diagnosis of deep vein thrombosis, pulmonary embolism, and disseminated intravascular coagulation. More recently, D-dimer levels have been correlated with atherosclerotic cardiovascular disease. In a recent case-control study of biomarkers for cardiovascular disease in human immunodeficiency virus (HIV)-infected adults, baseline D-dimer levels strongly correlated with all-cause mortality. Notably, the association between baseline D-dimer levels (...) understand the relationships between them and HIV infection. Healthy volunteers and HIV-infected adults 18 years of age or older may be eligible for this study. Two visits are involved, as follows: Visit 1 (screening visit to determine eligibility) Medical history and physical examination. Blood tests for HIV infection, blood counts, liver and kidney function. Pregnancy test for women who can become pregnant. Visit 2 Blood tests for hepatitis B and C Blood tests for markers of inflammation and blood

2008 Clinical Trials

55603. Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease

: Other Study ID Numbers: ICE-001 First Posted: October 20, 2008 Results First Posted: May 29, 2014 Last Update Posted: June 9, 2014 Last Verified: May 2014 Keywords provided by Allan Tenorio, MD, Rush University Medical Center: AIDS, HIV Additional relevant MeSH terms: Layout table for MeSH terms Immunologic Deficiency Syndromes Acquired Immunodeficiency Syndrome HIV Infections Immune System Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually (...) Transmitted Diseases, Viral Sexually Transmitted Diseases Slow Virus Diseases Ritonavir Lopinavir Tenofovir Emtricitabine Efavirenz HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Cytochrome P-450 CYP2C9 Inhibitors Cytochrome P-450

2008 Clinical Trials

55604. PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection

Update Posted: August 25, 2016 Last Verified: August 2016 Keywords provided by University of Pennsylvania: HIV infection DNA vaccine IL-12 adjuvant IL-15 adjuvant Additional relevant MeSH terms: Layout table for MeSH terms Infection Communicable Diseases HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System (...) a synthetic HIV-1 envelope protein (pEY2E1-B), Gag (gagCAM02), and Pol (pK2C1). Each plasmid is manufactured to a concentration of 4.0 mg/mL and is formulated with bupivacaine (0.25%) as a facilitating agent for DNA uptake. All plasmids (2.0 mg each gag, pol, env) are premixed by the manufacturer in the same vial. Biological: GENEVAX IL-12-4532 GENEVAX IL-12-4532 This molecular adjuvant plasmid contains nucleotide sequences necessary for expression of the human IL-12 protein. IL-12 DNA is formulated

2008 Clinical Trials

55605. Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients

viral load test. We will check routine safety labs done on HIV patients and also check homocysteine levels and creatine kinase level. We will evaluate homocysteine and IL6 levels at baseline, week 48, and week 96. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 33 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Pilot Study (...) Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Tenofovir Raltegravir Potassium Emtricitabine Atazanavir Sulfate Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Ritonavir Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents

2008 Clinical Trials

55606. A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)

Corp. Information provided by (Responsible Party): Merck Sharp & Dohme Corp. Study Details Study Description Go to Brief Summary: A study to test the safety and effect of twice daily raltegravir in a diverse cohort of patients currently infected with human immunodeficiency virus (HIV), where at least 50% are African American and at least 25% are female, either having received antiretroviral drugs before or not. Condition or disease Intervention/treatment Phase Human Immunodeficiency Virus Drug (...) /Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php Additional relevant MeSH terms: Layout table for MeSH terms Immunologic Deficiency Syndromes Acquired Immunodeficiency Syndrome HIV Infections Immune System Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Slow Virus Diseases Raltegravir Potassium Anti-HIV

2008 Clinical Trials

55607. Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection

for evaluation with a physical examination; blood tests for research purposes, safety, immune status and viral load; and response to any treatment they may be receiving. Other procedures, such as a biopsy, are done only as needed for standard medical practice, and informed consent is obtained before any such procedure is done. Treatment offered is consistent with standard medical practice; no experimental treatments are offered under this protocol. Condition or disease HIV Infections AIDS Opportunistic (...) Infections Detailed Description: This study is designed as a prospective natural history study with ongoing monitoring of HIV infection and HIV-related disease processes. Minimal studies scheduled for each visit will include: monitoring of immune status and viral load, routine safety laboratory tests, and collection of blood for research and storage. Treatment plans will be in accordance with standard medical practice, and the number and length of additional visits and diagnostic evaluations will vary

2008 Clinical Trials

55608. Healthy Teen Girls: HIV Risk Reduction

prevention female adolescent offenders sexual risk reduction alcohol and other drug abuse Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases (...) Healthy Teen Girls: HIV Risk Reduction Healthy Teen Girls: HIV Risk Reduction - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Healthy Teen Girls: HIV Risk Reduction The safety and scientific validity

2008 Clinical Trials

55609. Directly Observed Therapy for Community-Released HIV+ Prisoners

Directly Observed Therapy for Community-Released HIV+ Prisoners Directly Observed Therapy for Community-Released HIV+ Prisoners - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Directly Observed Therapy (...) for Community-Released HIV+ Prisoners (Connect) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00786396 Recruitment Status : Completed First Posted : November 6, 2008 Last Update Posted : August 20, 2014 Sponsor: Yale University Information provided by (Responsible Party): Yale University Study Details

2008 Clinical Trials

55610. A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-infected Women

: October 17, 2008 Last Update Posted : October 25, 2011 Sponsor: Kristine Patterson, MD Collaborator: Merck Sharp & Dohme Corp. Information provided by (Responsible Party): Kristine Patterson, MD, University of North Carolina, Chapel Hill Study Details Study Description Go to Brief Summary: The purpose of this research sub-study is to learn about the levels of an antiretroviral (ARV) medication called Raltegravir, and response to HIV virus in the genital tract of HIV-positive women. We would like (...) A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-infected Women A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-infected Women - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2008 Clinical Trials

55611. Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected Antiretroviral Treatment Experienced Children and Adolescents

Status : Completed First Posted : October 6, 2008 Results First Posted : February 1, 2016 Last Update Posted : February 1, 2016 Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Collaborator: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Information provided by (Responsible Party): National Institute of Allergy and Infectious Diseases (NIAID) Study Details Study Description Go to Brief Summary: Complications with current HIV (...) antiretroviral therapy have left many children and adolescents with limited therapeutic options due to drug resistance. The purpose of this study is to test the effectiveness and safety of Vicriviroc (VCV), an HIV entry inhibitor and CCR5 co-receptor antagonist. Condition or disease Intervention/treatment Phase HIV Infections Drug: Vicriviroc Phase 1 Phase 2 Detailed Description: Highly active antiretroviral therapy (HAART) that includes a protease inhibitor (PI) or a non-nucleoside reverse transcriptase

2008 Clinical Trials

55612. Analysis of HIV-1 Replication During Antiretroviral Therapy

and extracts the white cells and returns the rest of the blood components to the patient. Patients may also have an optional third clinic visit each year for another blood draw. Condition or disease HIV Infection Detailed Description: Combination antiretroviral therapy for human immunodeficiency virus serotype 1 (HIV-1) infection has resulted in profound reductions in viremia and is associated with marked improvements in morbidity and mortality. Therapy is not curative, however, and prolonged therapy (...) ): National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) ) Study Details Study Description Go to Brief Summary: This study will determine if the level of virus in HIV-infected patients taking antiretroviral medications for prolonged periods decreases or persists at a stable level. It will also examine whether new gene changes (mutations) occur during drug suppression. HIV-infected patients who are 18 years of age or older, have been enrolled

2008 Clinical Trials

55613. Influenza Vaccination at a Reduced Dose Using Mesotherapy in HIV/AIDS Patients at the Hadassah AIDS Center, Jerusalem

: Mesotherapy Not Applicable Detailed Description: We will test the effectiveness of mesotherapy as a vehicle for influenza vaccination.We will use 1:10th of the amount of seasonal trivalent influenza vaccine in approx.50 HIV/AIDS patients.A control group of approx.50 matched patients for age ,treatment schedule and immune status will receive the regular injection of trivalent vaccine. We will follow patients clinically for symptoms compatible with seasonal influenza and for direct side effects (...) for additonal information Responsible Party: Shlomo Maayan MD ; Director, Hadassah AIDS Center, Hadassah Medical organization ClinicalTrials.gov Identifier: Other Study ID Numbers: azw6gmHHMO-CTIL First Posted: September 25, 2008 Last Update Posted: October 9, 2008 Last Verified: September 2008 Keywords provided by Hadassah Medical Organization: Influenza in Humans Acquired Immune Deficiency Syndrome Immunization, Active Additional relevant MeSH terms: Layout table for MeSH terms Influenza, Human HIV

2008 Clinical Trials

55614. Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy

cohort 5.) First Posted : September 23, 2008 Last Update Posted : February 29, 2012 Sponsor: US Biotest, Inc. Collaborator: Tarix Pharmaceuticals Information provided by (Responsible Party): US Biotest, Inc. Study Details Study Description Go to Brief Summary: The purpose of this study is to test the safety of an investigational medication, TXA127, and its ability to increase T-lymphocyte counts, specifically CD4+ T-lymphocytes, in persons infected with human immunodeficiency virus who are taking (...) Numbers: TXA127-2008-001 First Posted: September 23, 2008 Last Update Posted: February 29, 2012 Last Verified: February 2012 Keywords provided by US Biotest, Inc.: HIV AIDS Human Immunodeficiency Virus CD4+ T-lymphocytes treatment Experienced Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune

2008 Clinical Trials

55615. Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma

not normally cause infections in people with healthy immune systems. Some of these infections can cause public health concerns, especially in areas with limited access to treatment. People who acquire opportunistic infections usually have diseases that affect their immune systems, such as human immunodeficiency virus (HIV), or do not have enough white blood cells to fight the infection. However, some people acquire opportunistic infections even though they have normal amounts of white blood cells (...) disseminated or lymphatic nontuberculous infections have had other opportunistic infections (OI), such as salmonella, penicilliosis, and histoplasmosis. However, they have normal lymphocyte counts and are human immunodeficiency virus (HIV) negative. Therefore, the identification of autoantibodies to a critical cytokine, the occurrence of opportunistic infections, and the lack of other common explanations suggests that this is an important population to study. We propose to enroll patients in a natural

2008 Clinical Trials

55616. Culturally-Tailored HIV Risk Reduction for African-American MSM

and Resilient Charles D Productions Milwaukee LGBT Community Center Information provided by: Centers for Disease Control and Prevention Study Details Study Description Go to Brief Summary: The purpose of this study to conduct a small randomized control trial to compare the relative effectiveness of a single-session of HIV testing and counseling risk reduction intervention (HCT-only) to an enhanced intervention that includes the standard HCT intervention plus a theory-based and culturally-tailored group (...) Actual Primary Completion Date : March 2010 Actual Study Completion Date : March 2010 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: 1 Participants receive HIV counseling and testing and 8 intervention sessions to assist them with reducing unsafe sexual behaviors. Behavioral: Project ABLE Participants will receive HIV counseling and testing. Those selected for the intervention arm will attend small

2008 Clinical Trials

55617. A Network Intervention for Reducing Sexual Risk for HIV With African American Men Who Have Sex With Men (AA MSM)

is to determine whether the new intervention is more efficacious at reducing high risk sexual behaviors than the standard normal of care provided to the public (a single session of individual HIV counseling and testing. Condition or disease Intervention/treatment Phase HIV Infections Behavioral: Unity in Diversity Not Applicable Detailed Description: The intervention increases participants' personal level of knowledge and skills concerning HIV prevention and inspires participants to diffuse the information (...) : March 2010 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: 1 HIV/STI counseling and testing and a 7 session intervention to increase participants' level of knowledge and skills concerning HIV prevention (to decrease HIV acquisition or transmission) and to diffuse the information to their social network Behavioral: Unity in Diversity HIV/STI counseling and testing and a 7 session intervention to increase

2008 Clinical Trials

55618. The Detection of Drug-Resistant HIV-1 in Taiwan

Taiwan University Hospital Study Details Study Description Go to Brief Summary: To assess the HIV resistance rate to variable antiretroviral agents in Taiwan, especially in patients with treatment failure, and to know the correlation between the drug resistance pattern and the HIV subtype, we will enroll a total of 150~200 HIV-1-infected subjects to perform genotypic resistance testing and try to establish facility of phenotypic resistance testing. Condition or disease HIV Infections Detailed (...) Description: Drug-resistant HIV strains may develop during antiretroviral therapy, and transmission of drug-resistant virus has been documented to be possible. The emergence of drug resistance in HIV has been associated with suboptimal virologic response to antiretroviral therapy [1]. The likelihood that a patient will acquire drug-resistant virus is related to the prevalence of drug resistance in the population with specific high-risk behaviors. In the western countries, studies suggest

2008 Clinical Trials

55619. No Excuses/Sin Buscar Excusas Intervention to Reduce Latino Men's HIV Risks

: November 2009 Actual Study Completion Date : November 2009 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: video Behavioral: Video (group-delivered video-based intervention) group-delivered video-based intervention Active Comparator: HCT Offer of HIV counseling and testing Behavioral: HCT Offer of HIV counseling and testing Outcome Measures Go to Primary Outcome Measures : Sexual risk behavior [ Time Frame (...) terms HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases

2008 Clinical Trials

55620. Integrated Treatment of Marijuana Abuse for HIV+ Youth

(NIMH) Information provided by (Responsible Party): University of North Carolina, Chapel Hill Study Details Study Description Go to Brief Summary: This is an exploratory study that will adapt and test a combined cognitive behavioral treatment and contingency management intervention for alcohol and/or marijuana abuse for use in HIV-infected adolescents. Condition or disease Intervention/treatment Phase HIV Infections Behavioral: Focus Group Behavioral: First Intervention Trial Behavioral (...) Rating Scale Individual behavior therapy Individual cognitive problem solving Motivational enhancement therapy HIV-Positive Youth With Substance Abuse Complementary Therapies Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Marijuana Abuse Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Substance-Related Disorders

2008 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>